Carisoprodol Generic soma

Product Name	Price	Order link
Generic Fioricet 50/325/40 mg - 90 Tabs	$65	Order
Generic Fioricet 50/325/40 mg - 30 Tabs	$50	Order
Tramadol 50 mg - 180 Tabs	$99	Order
Tramadol 50 mg - 90 Tabs	$65	Order
Tramadol 50 mg - 30 Tabs	$50	Order
Carisoprodol 350mg - 30 Tabs	$45	Order
Carisoprodol 350mg - 90 Tabs	$70	Order
Soma 350mg - 30 Tabs	$50	Order
Soma 350mg - 90 Tabs	$75	Order

The Chemical Basis for Soma Abuse

Soma itself is probably not addicting. However, the liver metabolizes Soma into meprobamate, a different medication. Meprobamate has significant anti-anxiety properties and is a controlled substance with the potential to be abused. Theoretically, it is possible that people whose livers are more efficient at metabolizing Soma into meprobamate may be more likely to abuse Soma.

 

Limiting Soma Abuse

Soma is approved only for short-term use (for a maximum of two or three weeks). Taking it for longer periods of time could increase the risk of dependence and possibly abuse. More importantly, people with a tendency towards alcohol or drug abuse are at a high risk for abusing Soma. Therefore, Soma is not a good choice for people with such problems. Other muscle relaxants with no abuse potential would be much more appropriate. Soma abuse is also more likely when people take Soma together with alcohol or other medications with abuse potential. Avoiding alcohol or addicting medications may help limit Soma abuse.

Because Soma is not a controlled substance, people sometimes think that it will be easier to get a prescription for Soma, compared to other potentially addicting medications (such as narcotics). However, most healthcare providers are quite familiar with the problems associated with Soma. Most healthcare providers react to a request for Soma just as they would react for a request for a controlled substance (usually with caution and sometimes suspicion).

In the postmarketing experience with SOMA, cases of dependence, withdrawal, and abuse have been reported with prolonged use. Most cases of dependence, withdrawal, and abuse occurred in patients who have had a history of addiction or who used SOMA in combination with other drugs with abuse potential. However, there have been post-marketing adverse event reports of SOMA-associated abuse when used without other drugs with abuse potential. Withdrawal symptoms have been reported following abrupt cessation after prolonged use. To reduce the chance of SOMA dependence, withdrawal, or abuse, SOMA should be used with caution in addiction-prone patients and in patients taking other CNS depressants including alcohol, and SOMA should not be used more than two to three weeks for the relief of acute musculoskeletal discomfort.

SOMA, and one of its metabolites, meprobamate (a controlled substance), may cause dependence

Nonclinical Toxicology

Carcinogenesis, Mutagenesis, Impairment of Fertility

Long term studies in animals have not been performed to evaluate the carcinogenic potential of carisoprodol.

SOMA was not formally evaluated for genotoxicity. In published studies, carisoprodol was mutagenic in the in vitro mouse lymphoma cell assay in the absence of metabolizing enzymes, but was not mutagenic in the presence of metabolizing enzymes. Carisoprodol was clastogenic in the in vitro chromosomal aberration assay using Chinese hamster ovary cells with or without the presence of metabolizing enzymes. Other types of genotoxic tests resulted in negative findings. Carisoprodol was not mutagenic in the Ames reverse mutation assay using S. typhimurium strains with or without metabolizing enzymes, and was not clastogenic in an in vivo mouse micronucleus assay of circulating blood cells.

SOMA was not formally evaluated for effects on fertility. Published reproductive studies of carisoprodol in mice found no alteration in fertility although an alteration in reproductive cycles characterized by a greater time spent in estrus was observed at a carisoprodol dose of 1200 mg/kg/day. In a 13-week toxicology study that did not determine fertility, mouse testes weight and sperm motility were reduced at a dose of 1200 mg/kg/day. In both studies, the no effect level was 750 mg/kg/day, corresponding to approximately 2.6 times the human equivalent dosage of 350 mg four times a day, based on a body surface area comparison. The significance of these findings for human fertility is not known.